October 2016. ADC Therapeutics SA (ADCT), Lausanne, Switzerland, announced that it has raised USD 105 m through a private placement of shares. The financing was oversubscribed and supported by both new and existing investors, including Auven Therapeutics, the Wild Family Office and AstraZeneca. Since inception in 2012, ADCT has raised a total of USD 255 m in equity.

ADCT is an oncology drug development company that specializes in the development of proprietary antibody drug conjugates targeting major types of hematological malignancies and solid tumors.

The financing proceeds will be used to accelerate the progress of ADCT's pipeline in clinical development, and to fund commercial manufacturing processes for its lead programs.

Homburger advised ADCT in this transaction. The Homburger team was led by partner Dieter Gericke and included associates Guy Deillon and Daniel Häusermann as well as junior associate Natassia Gili (all Corporate | M&A).